Patents by Inventor Hermans Jan
Hermans Jan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9579329Abstract: The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15?, 16?, 17?-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse.Type: GrantFiled: August 9, 2012Date of Patent: February 28, 2017Assignee: Estetra S.P.R.L.Inventors: Wout Wouters, Herman Jan Tijmen Coelingh Bennink, Ludivine Petit, Jean-Michel Foidart
-
Patent number: 9561238Abstract: The present invention relates to a method of treating or preventing estrogen-suppressed tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.Type: GrantFiled: February 12, 2015Date of Patent: February 7, 2017Assignee: Donesta Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Patent number: 9541515Abstract: A characterization apparatus for characterizing a liquid containing insoluble particles includes a housing including an inlet portion defining an inlet passage between an inlet end and a first channel end, a channel portion defining a measurement channel between the first channel end and a second channel end, and an outlet portion defining an outlet passage between the second channel end and an outlet end. The channel portion includes a first electrode and a second electrode at a first and second side of the channel. The apparatus also includes a measurement device configured for measuring an electric measure representative for properties of the liquid flowing between the first electrode and the second electrode. The inlet passage gradually changes shape from the inlet end to the first channel end. The outlet passage gradually changes shape from the second channel end to the outlet end.Type: GrantFiled: July 13, 2015Date of Patent: January 10, 2017Assignee: Xeikon IP B.V.Inventors: Kim Louis Jozephus Hoefnagels, Herman Jan Godelieve Van De Straete, Herwig Joannes Van Dooren, Bjorn Leynen
-
Publication number: 20160310506Abstract: The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight of 50-1,000 mg and containing at least 0.1 mg of an estetrol component selected from estetrol, estetrol esters and combinations thereof. This solid dosage unit consists of: 4-95 wt. % of granules consisting of: 3-80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; 20-97 wt. % C4-C12 sugar alcohol; 0-45 wt. % of one or more other pharmaceutically acceptable ingredients; and 5-96 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage units of the present invention are particularly suited for sublingual, buccal or sublabial administration of the estetrol component.Type: ApplicationFiled: December 10, 2014Publication date: October 27, 2016Applicant: Donesta Bioscience B.V.Inventors: Johannes Jan PLATTEEUW, Herman Jan Tijmen COELINGH BENNINK
-
Publication number: 20160202663Abstract: A system for use in image reproduction, the system includes at least a first light emitting unit and a second light emitting unit. The first light emitting unit includes a first cooling means arranged for cooling the first light emitting unit. The second light emitting unit includes a second cooling means arranged for cooling the second light emitting unit independently of the first light emitting unit. The first light emitting unit has a first elongate emitting area. The second light emitting unit has a second elongate emitting area. A control unit controls the cooling of at least one of the first cooling means and the second cooling means such that at least one of the first elongate emitting area and the second elongate emitting area, respectively, has a desired length.Type: ApplicationFiled: December 31, 2015Publication date: July 14, 2016Inventors: Herman Jan Godelieve Van De Straete, Jurgen Norbert Bart Devlieghere
-
Patent number: 9322045Abstract: The present invention relates to a recombinant host cell for the production of a compound of interest. The invention further relates to a method for the production of such host cell. The invention further relates to the production of a compound of interest. The invention further relates to isolated polynucleotides and vectors and host cells comprising said polynucleotides.Type: GrantFiled: April 10, 2014Date of Patent: April 26, 2016Assignee: DSM IP ASSETS B.V.Inventors: Noël Nicolaas Maria Elisabeth Van Peij, Herman Jan Pel, Thibaut José Wenzel, Adriana Marina Riemens, Ilse De Lange
-
Patent number: 9295720Abstract: The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment of prostate cancer. Said immunogenic polypeptides are provided by the zona pellucida (ZP) (glyco)proteins. ZP (glyco)proteins and fragments thereof that can induce a CD8+ and/or CD4+ T cell response as well as nucleic acid sequences encoding them can suitably be used in the present immunotherapeutic strategies.Type: GrantFiled: August 29, 2011Date of Patent: March 29, 2016Assignee: PANTARHEI BIOSCIENCE B.V.Inventor: Herman Jan Tijmen Coelingh Bennink
-
Publication number: 20160011137Abstract: A characterization apparatus for characterizing a liquid containing insoluble particles includes a housing including an inlet portion defining an inlet passage between an inlet end and a first channel end, a channel portion defining a measurement channel between the first channel end and a second channel end, and an outlet portion defining an outlet passage between the second channel end and an outlet end. The channel portion includes a first electrode and a second electrode at a first and second side of the channel. The apparatus also includes a measurement device configured for measuring an electric measure representative for properties of the liquid flowing between the first electrode and the second electrode. The inlet passage gradually changes shape from the inlet end to the first channel end. The outlet passage gradually changes shape from the second channel end to the outlet end.Type: ApplicationFiled: July 13, 2015Publication date: January 14, 2016Inventors: Kim Louis Jozephus Hoefnagels, Herman Jan Godelieve Van De Straete, Herwig Joannes Van Dooren, Bjorn Leynen
-
Publication number: 20150197760Abstract: The present invention relates to isolated Rasamsonia promoter DNA sequences, to DNA constructs, vectors, and host cells comprising these promoters in operative association with coding sequences. The present invention also relates to methods for expressing a gene and/or producing a biological compound using the new promoters isolated. The present invention also relates to methods for altering the transcription level and/or regulation of an endogenous gene using the new promoter of the invention.Type: ApplicationFiled: June 17, 2013Publication date: July 16, 2015Inventors: Alrik Pieter Los, Wilbert Herman Marie Heijne, Herman Jan Pel, Robbertus Antonius Damveld, Brenda Vonk
-
Publication number: 20150150887Abstract: The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.Type: ApplicationFiled: February 12, 2015Publication date: June 4, 2015Applicant: Pantarhei Bioscience B. V.Inventors: Herman Jan Tijmen COELINGH BENNINK, Evert Johannes Bunschoten
-
Patent number: 9040509Abstract: One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 ?g/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors; and (ii) a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing.Type: GrantFiled: January 31, 2011Date of Patent: May 26, 2015Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten, Christian Franz Holinka
-
Patent number: 9034854Abstract: The present invention relates to a method of treating or preventing estrogen-sensitive tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.Type: GrantFiled: July 11, 2003Date of Patent: May 19, 2015Assignee: PANTARHEI BIOSCIENCE B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Publication number: 20150133413Abstract: The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.Type: ApplicationFiled: January 20, 2015Publication date: May 14, 2015Applicant: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen COELINGH BENNINK, Evert Johannes BUNSCHOTEN
-
Patent number: 8987240Abstract: The present invention relates to a method of treating or preventing estrogen-suppressed tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.Type: GrantFiled: October 23, 2003Date of Patent: March 24, 2015Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten
-
Publication number: 20150050696Abstract: The present invention relates to a method based on the use of restriction enzyme digestion and ligation via cleavage sites, thereby to prepare two or more standardized expression cassettes.Type: ApplicationFiled: March 27, 2013Publication date: February 19, 2015Inventors: Johannes Andries Roubos, Herman Jan Pel, Bernard Meijrink
-
Publication number: 20140248662Abstract: The present invention relates to a recombinant host cell for the production of a compound of interest. The invention further relates to a method for the production of such host cell. The invention further relates to the production of a compound of interest. The invention further relates to isolated polynucleotides and vectors and host cells comprising said polynucleotides.Type: ApplicationFiled: April 10, 2014Publication date: September 4, 2014Applicant: DSM IP ASSETS B.V.Inventors: Noël Nicolaas Maria Elisabeth VAN PEIJ, Herman Jan PEL, Thibaut Jose WENZEL, Adriana Marina RIEMENS, Ilse DE LANGE
-
Publication number: 20140235598Abstract: The present invention relates to a tablet having a weight of 30-200 mg and consisting of: 60-100 wt. % of granules consisting of: 50-90% by weight of the granules of dehydroepiandrosterone (DHEA); 6-35% by weight of the granules of microcrystalline cellulose; 0-20% by weight of the granules of one or more other pharmaceutically acceptable granule ingredients; and 0-40 wt. % of one or more other pharmaceutically acceptable tablet components. These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.Type: ApplicationFiled: July 17, 2012Publication date: August 21, 2014Inventors: Herman Jan Tijmen Coelingh Bennink, Johannes Jan Platteeuw
-
Publication number: 20140235882Abstract: The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3,15?,16?,17?-tetraol (estetrol), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, wherein A is a protecting group and B is —Si(R2)3. The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is a protecting group, via said silyl enol ether derivative.Type: ApplicationFiled: July 18, 2012Publication date: August 21, 2014Inventors: Johannes Jan Platteeuw, Herman Jan Tijmen Coelingh Bennink, Franciscus Wilhelmus Petrus Damen, Michiel Christine Alexander Van Vliet
-
Patent number: 8801627Abstract: Sampler for self-sampling of samples from a body cavity, such as cervical samples. Optimum accessibility of the cervix is achieved through the sampler comprising a rigid plastic tube which is rounded at the front side. During its introduction, the sampler can accurately be moved to the cervix. The sampler is surrounded by the vagina and can prevent leakage of flushing liquid, and it is possible to use a relatively small quantity of flushing liquid while producing a sample with a high concentration of cervical cells. It is possible to reach the sampling location in a simple and more accurate way which does not damage tissue. As a result of the tube simultaneously being designed as a cylinder for a plunger, it is possible, to flush the desired location with a solution using a cylinder-plunger and, to take the sample by drawing the plunger back.Type: GrantFiled: September 23, 2004Date of Patent: August 12, 2014Assignee: Pantarhei Bioscience B.V.Inventors: Martinus Antonius Hermanus Maria Wiegerinck, Herman Jan Tijmen Coelingh Bennink, Petrus Johannes Boerrigter
-
Publication number: 20140200202Abstract: The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3,15?,16?,17?-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse.Type: ApplicationFiled: August 9, 2012Publication date: July 17, 2014Applicant: Estetra S.P.R.L.Inventors: Wout Wouters, Herman Jan Tijmen Coelingh Bennink, Ludivine Petit, Jean-Michel Foidart